BioPharmSignal logoBioPharmSignal

Biotech News

Caribou Biosciences Reports Third Quarter 2026 Financial Results

Caribou (CRBU)CaribouEarnings

BERKELEY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026. Third quarter 2026 financial results Licensing and other third-party revenue: Revenue from licensing and other third-party agreements was $1.6

Related news

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

SANASana Biotechnology2026-11-05 21:05 EST

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

SRPTSarepta Therapeutics2026-11-05 21:05 EST

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

View all latest news

Caribou

Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells. Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic...

Recent company news

CRBUCaribou2026-11-05 21:05 EST

Caribou Biosciences Reports Third Quarter 2026 Financial Results

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

CRBUCaribou2026-10-06 20:05 EST

Caribou Biosciences to Evaluate Strategic Alternatives

CRBUCaribou2026-08-13 20:05 EST

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

CRBUCaribou2026-06-29 12:00 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Stock data

Close
0.41 USD
Market cap
230.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States